Sepsis, Exosomes, Longevity, Bioeconomy
In this issue:
- Sepsis: Targeting a silent killer
- Exosomes: Nanovesicles take personalised medicine to the next level
- Longevity: Endogenous biomarker points to an increased life expectancy
- Bioeconomy: Can carbon dioxide emissions act as a feedstock for industry?
- Interview with Hans-Georg Eichler, EMA‘s Senior Medical Officer
- News from our partner associations European Biotechnology Network, EAPB, EDMA, DIA, BIO Deutschland and the Swiss Biotech Association
- ... and our Special CROs & CMOs.
Real World Data: Beyond clinical trials
Jim Omel has an intimate knowledge of drugs from many different perspectives. For years, he prescribed them as a physician. As a pharmacist, he...
Exosomes: Extracellular and extraordinary
Even though they’re in the nanometer range, extracellular vesicles (EVs) could start to make it big in the next few years. Long ignored as “cell...
Sepsis: Targeting a silent killer
When he was born in 1947, nobody could have predicted that the baby born Cassius Clay would become a three-time boxing world heavyweight champion who...